Prof. Philip Scheltens

Therapeutic Areas

  • CNS diseases

Useful Links

Philip Scheltens, MD, PhD is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam, as well as Honorary Professor of Neurology at University College London.

Theraputic areas and expertise

From 2011-2015, he was the scientific director of the Dutch Pearlstring Institute (PSI). In 2013, he was appointed vice-chair of the board of the Dutch “Deltaplan Dementie”. Since 2015, he has been a member of the board of the Royal Academy of Sciences and Art.

His main clinical and research interests are dementia in the broadest sense, from basic research to care and translational research. He is active in the field of biomarkers and clinical trials and has been the (inter) national PI for many studies, including Phase I–III multicentre clinical trials.

He is founder of, and has directed since 2000, the VUmc Alzheimer Center in The Netherlands, and during this period, he has produced over 50 PhD theses. He also founded the Alzheimer Research Center, a center dedicated to and specialised in Alzheimer clinical trials, where he is now a scientific adviser and member of the Board of Trustees.

Dr. Scheltens is an active member of several societies, including the Dutch Society for Neurology, the AAN, the Alzheimer Imaging Consortium, the ISTAART Consortium, and the ECNP. He has been instrumental in organising several national and international conferences, including the Imaging Symposium attached to AAIC. He is member of the management board of the dementia panel of the EAN.

He was Associate Editor of the Journal of Neurology, Neurosurgery and Psychiatry until 2010. He was Chief Editor of the official journal of the Dutch Society of Neurology until November 2008. He is co-editor-in-chief of Alzheimer’s Research & Therapy and acts as an ad hoc reviewer of scientific articles for all of the major journals. He has authored >730 peer reviewed papers and >50 book chapters. His current Hirsch factor is 117 (Google Scholar). Dr Scheltens co-edited the books, Magnetic Resonance in Dementia (Springer), Neuroimaging in dementia (Springer) and Functional Magnetic Resonance Imaging: Clinical Applications (Oxford University Press). In September 2015, he published his first book for the general public on Alzheimer’s in Dutch (Het Alzheimermysterie).

He was one of the founding fathers of, and acted as Treasurer of, the International Society for Vascular Behavioural and Cognitive Disorders (Vas-Cog) until 2011. He is member of the local organising committee of the EAN congress in Amsterdam in 2017 and the VASCOG congress in October 2016 in Amsterdam.


1. Scheltens P, Blennow K, Breteler MMB, De Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Seminar: Alzheimer’s Disease. Lancet 2016; In this invited Seminar for Lancet, I had the chance to review the current landscape of AD research and give my vision on the future, supported by 6 distinguished collegues in the field.

2. Ossenkoppele R, Jansen WJ, Rabinovici GD, …..Scheltens P, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015 May 19;313(19):1939-49. doi: 10.1001/jama.2015.4669. PubMed PMID: 25988463; PubMed Central PMCID: PMC4517678. Under my supervision, Rik Ossenkoppele and Pieter Jelle Visser collected amyloid PET data from as many sources possible. We were able to show the age dependence and influence of APOE on the largest set to date, enabling design of future drug studies.

3. Van der Flier WM, Pijnenburg YAL Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ε4 allele. Lancet Neurol 2011;10:280-288. Ever since my thesis in 1993, I have been convinced of the heterogeneity of AD. In this article, we convincingly show that the APOE gene does more than advancing the age of onset, but has particular relevance to the clinical phenotype as well.

4. Dubois B, Feldman HH, Jacova C, ………..Scheltens P. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 2007;6:734-746. I am proud and happy to have been at the forefront of the development of the new IWG criteria and think that the first article in 2007 preluded the concept change that took place after that. In this article we first showed that AD could be diagnosed in a much earlier phase and that AD is a continuum rather than a step wise process with MCI in between.

5. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-972. Although now more than 24 years ago, this article keeps being cited. We introduced a new method, simple but accurate, which is now implemented worldwide and helped introducing MRI in clinical practice.

Personal website :